Ionis already has a pipeline bursting at the seams with antisense projects – some more successful than others. But the company clearly believes it has capacity for more, today announcing a gene editing collaboration with Metagenomi worth $80m up front.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,